Compare · BIOT vs NVO
BIOT vs NVO
Side-by-side comparison of Biotech Acquisition Company (BIOT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.24B, about 14796.5x BIOT ($12.9M).
- Over the past year, BIOT is down 85.4% and NVO is down 30.1% - NVO leads by 55.3 points.
- NVO has been more active in the news (7 items in the past 4 weeks vs 3 for BIOT).
- NVO has more recent analyst coverage (25 ratings vs 0 for BIOT).
- Company
- Biotech Acquisition Company
- Novo Nordisk A/S
- Price
- $0.44+1.29%
- $43.24+0.09%
- Market cap
- $12.9M
- $191.24B
- 1M return
- +13.09%
- -6.93%
- 1Y return
- -85.41%
- -30.09%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- News (4w)
- 3
- 7
- Recent ratings
- 0
- 25
Biotech Acquisition Company
Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BIOT
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
- INSTINCT BIO Provides Operational Update on Indonesia Growth Platform and Product Development Initiatives
- SEC Form 6-K filed by Biotech Acquisition Company
- Instinct Bio Announces Strategic Collaboration with PT PARVA CANDELA to Develop Cosmetics Business in Indonesia
- SEC Form 6-K filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
- BIOT to Launch Indonesia’s First Subscription-Model Beauty Clinics Under Its Own Japanese Brand “GENRÊVER CLINIC” — Building a Recurring-Revenue Platform in One of Asia’s Fastest-Growing Aesthetics Markets
- SEC Form 20-F filed by Biotech Acquisition Company
- SEC Form 6-K filed by Biotech Acquisition Company
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Morgan Stanley with a new price target
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Deutsche Bank
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg